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http://dx.doi.org/10.10dementia risk score cardiovascular risk factors , aging and dementia study (CAIDE) constituting age,
education, hypertension, obesity, and hyperlipidemia in a larger, more diverse population. Our second
aim was to improve the CAIDE risk score by additional midlife risk factors.
Methods: This retrospective cohort study was conducted in an integrated health care delivery
system. A total of 9480 Kaiser Permanente members who participated in a health survey study
(age range, 40–55 years) from 1964 to 1973 were included in this study. Dementia diagnoses from
primary care and medical specialist visits were collected from January 1, 1994 to January 16,
2006, using International Classification of Diseases 9 codes 290.0, 290.1 for “possible dementia,”
and 331.0 and 290.4 for “specialist confirmed dementia.” Risk model prediction and validation
were examined with the C statistic, net reclassification improvement, and integrated discrimination
improvement. Dementia risk per sum score was calculated with Kaplan-Meier estimates.
Results: A total of 2767 participants (25%) were diagnosed with any type of dementia, of which
1011 diagnoses (10.7%) were specialist-confirmed diagnoses. Average time between midlife exam-
ination and end of follow-up was 36.1 years. The CAIDE risk score replicated well with a C statistic
of 0.75, quite similar to the original CAIDE C statistic of 0.78. The CAIDE score also predicted well
within different race strata. Other midlife risk factors (central obesity, depressed mood, diabetes
mellitus, head trauma, lung function, and smoking) did not improve predictability. The risk score al-
lowed stratification of participants into those with 40-year low (9%) and high (29%) dementia risk.
Conclusions: A combination of modifiable vascular risk factors in midlife is highly predictive of the
likelihood of dementia decades later. Possible dementia prevention strategies should point to a life
course perspective on maintaining vascular health.
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Smoking1. Introduction
Currently, projections posit there will be a fourfold in-
crease to 106.8 million dementia cases worldwide by 2050
[1], yet there’s no curative treatment available. Dementiasults for and receives research support from Boeh-
thor. Tel.: 1510-891-3461; Fax: 1510-891-3761.
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nt matter  2014 The Alzheimer’s Association. All rights r
16/j.jalz.2013.05.1772has a long preclinical period during which there are no no-
ticeable cognitive impairments, but likely neurodegenerative
changes are occurring [2]. To prevent dementia, early iden-
tification of individuals at high risk of dementia is crucial.
Early identification may be achieved by the development
of prognostic models or risk scores at midlife. The focus
on midlife is particularly germane for dementia prevention
for two reasons: (i) midlife is early enough to ensure forward
temporal associations between risk factors and dementia
before neurodegeneration or cognitive changes haveeserved.
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and direction of risk factors for dementia vary throughout the
life course [3–7].
Risk scores have been used successfully in several other
fields in medicine. The first and best known example is the
Framingham Risk Score [8], which is used to guide interven-
tion or prevention strategies for cardiovascular disease. In
2006, the first dementia risk score was designed to predict
20-year dementia risk among middle-age people. The
risk score was created with data from 1449 Finnish partici-
pants of the cardiovascular risk factors, aging, and dementia
study (CAIDE) study [9,10]. TheCAIDE risk score, based on
age, education, hypertension, obesity, and hyperlipidemia in
midlife, has an area under the curve (receiver–operating
characteristic [ROC]) of 0.77. It is critical to evaluate
further the predictability in larger, less homogeneous
populations and to evaluate whether it can be improved by
the consideration of other important midlife risk factors
such as diabetes mellitus.
The objective of our study was twofold: (i) to validate
externally the CAIDE risk score in a large (n 5 9480),
diverse population of members of an integrated health care
delivery system in the United States and (ii) to try to improve
the predictability with the testing of additional midlife risk
factors.2. Subjects and methods
2.1. Population
The study population consists of members of the Kaiser
Permanente Medical Care Program of Northern California
(KPNC) who participated in voluntary periodic multiphasic
health checkups (MHCs) in San Francisco and Oakland, CA,
between 1964 and 1973 when they were middle-aged [11].
The MHC was performed as part of routine medical care
and included a comprehensive questionnaire (sociodemo-
graphic, behavioral, medical history, and current health
questions), a clinical examination (including anthropometry
at some sites), and a standardized blood draw. KPNC is
a nonprofit group/practice integrated health delivery system
that covers more than one-third of the population in the
geographic areas served. Kaiser Permanente members are
representative of the sociodemographics of the local popula-
tion, except for the extreme tails of low- and high-income
distribution [12].
2.2. Data collection
During the MHCs, participants were interviewed, and
information on demographics, lifestyle, and medical history
was collected [11]. A questionnaire was used to screen for
head trauma (Have you ever had head injuries bad enough to
knockyouout?) and for depressedmood (Doyouoften feel un-
happy or depressed?). Study participants who answered
yes were classified as having the condition [11,13,14].
Trained technicians performed all anthropometric measuresaccording to the Nutritional Academy of Anthropometry
Standards. The sagittal abdominal diameter—the distance
between the back surface and the top of the abdomen at the
level of the iliac crest—was measured after gentle expiration
with the patient in a standing position using an
anthropometer. Height and weight were measured using
a balance beam scale calibrated to the nearest 8 oz. and
a tape measure with standard positioning [14]. Body mass in-
dex (BMI) was calculated as weight in kilograms divided by
height in meters squared. Systolic blood pressure (SBP) was
measured according to standard procedures in the supine
position [14]. Lung function tests included forced expiratory
volume in 1 second (FEV1) using a Vertek VR5000 Lung
Function computer (Electro/Med. Instruments, Houston,
TX) according to methods described previously [11]. Blood
was drawn for total serum cholesterol, and levels were mea-
sured with an autoanalyzer (Technicon Co., White Plains,
NY) from 1964 to 1968, with an autochemist (AGA, Stock-
holm, Sweden) from 1969 to 1972, and with an autoanalyzer
(model SMA-12, Technicon) in 1973 [11,14]. Diabetes
mellitus was defined by having one of the following: 1) self-
report of physician-diagnosed diabetes mellitus, 2) use of
insulin, or oral hypoglycemic agents, 3) a fasting glucose
level (last food eaten, 8 hours or more) 140 mg/dl or more,
or a nonfasting (last food eaten, 4 hours or less) glucose
level of 200 mg/dL or more. If all four criteria for diabetes
mellitus were negative, it was coded as no diabetes.2.3. Analytical cohort
Our retrospective cohort was based on mortality and de-
mentia status information in 1994. Dementia diagnosis as-
certainment commenced in 1994, when outpatient records
became available. Of the 18,231 Kaiser Permanente (KP)
members between 40 years and 55 years who participated
between 1964 and 1973 in the full MHC (including the an-
thropometry examination), 14,282 were still a KP member
and alive in 1994. Those with missing data in the MHC on
education, or any of the following variables—BMI, SBP,
cholesterol, diabetes mellitus, depressed mood, pulmonary
function, and race (n 5 2035)—were excluded, which
resulted in a validation cohort of 12,247 subjects. Not con-
sidering “possible dementia” diagnosis resulted in a refine-
ment cohort of 9480 subjects. The 2035 KP members that
were excluded because of missing MHC data were, on aver-
age, 46.4 6 4.4 (standard deviation) years of age and 57%
were female.2.4. Diagnosis of dementia
Dementia diagnoses were ascertained through electronic
medical records from a database that contains diagnoses from
all outpatient encounters at Kaiser Permanentemedical centers
and clinics starting in 1994. Diagnoses included initial diagno-
ses made in primary care “possible dementia”(International
Classification of Diseases, ninth revision (ICD-9) codes
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ical specialist in a memory clinic or neurology department
“specialist-confirmed dementia”(ICD-9 codes 331.0, 290.4x,
and 290.1x). Diagnoses were ascertained from January 1994
to June 2006, when the MHC participants were, respectively,
61 years to 85 years and 73years to 97years. Thevalidation co-
hort, used for the first aim of our study, included any type of de-
mentia (both possible dementia and specialist-confirmed
dementia diagnoses). However, the codes used for possible de-
mentia diagnosis in KPNC’s primary care setting can also used
for people with milder forms of cognitive impairment and tend
tohavea lower specificity than specialist diagnoses.To increase
the specificity of the dementia diagnosis for the second aim of
this study(refinementof the risk score),wecreateda refinement
cohort that only included Alzheimer’s disease (AD) (ICD-9
ClinicalModification [CM] code 331.0) and vascular dementia
(ICD-9 CM code 290.4) diagnosed by a medical specialist in
a memory clinic or neurology department and did not consider
“possible dementia” cases.
2.5. Statistical analysis
Differences in midlife characteristics by dementia status
were assessed using Student’s t test and c2 test. Consistent
with the CAIDE score methodology, variables were catego-
rized as age, years younger than 47, 47 years to 53 years, or
54 years to 55 years; education, 0 to 6 years, 7 to 9 years, or
10 years or more [10], hypertension as SBP more than
140 mmHg, obesity as a BMI greater than 30 kg/m2, and to-
tal cholesterol greater than 250.9 mg/dL. New variables
were defined as central obesity, sagittal abdominal diameter
more than 25 cm [15]; and poor pulmonary function as the
lowest quintile of forced expiratory volume (0.2–1.8 L).
Smoking was defined as never or ever, with the category
of ever including current and former.
2.6. External validation of CAIDE risk score
Variables were allocated the points of the original risk
score. The validation of the CAIDE risk score was
performed with logistic regression analyses, with CAIDE
risk score as the only predictor, paralleling the original anal-
ysis in the CAIDE cohort. Analyses were also stratified by
race. The Kaplan-Meier method was used to provide
point and interval estimates of observed 40-year population-
level dementia risk for each level of the CAIDE risk score.
2.7. Predictive accuracy
Predictive accuracy of the model was assessed based on
discrimination and calibration. Discrimination refers to the
ability of the model to distinguish accurately between those
whodevelopdementia from thosewhodonot. For comparison
with the original study, we calculated the C statistic for the
dichotomous outcome of ever/never dementia as the area un-
der the ROC curve [16]. In addition, we assessed discrimina-
tion more appropriately in the context of survival analysisusing Harrell’s C statistic [17], which can be interpreted as
the probability that a subject from the event group has a higher
predicted probability of having an event than a subject from
the nonevent group. Calibration refers to the extent to which
predicted risk agrees with observed risk. We assessed this
by calculating the Hosmer-Lemeshow c2 test [17].2.8. Testing of additional midlife risk factors
First we added the “new” potential risk factors separately
to a model with all the CAIDE risk factors in both a logistic
regression and a Cox proportional hazards ratio analysis.
Logistic regression analysis was first used for reasons of
direct comparison with the originally published CAIDE
logistic regression models. Next, we applied Cox propor-
tional hazard models for prediction modeling, because it ac-
counts for time during the 121-year period of follow-up for
dementia, with appropriate right censoring for (i) termina-
tion of health plan membership (defined as a lag of 3 months
or more), (ii) death, or (iii) the end of the study period on
June 1, 2006. The newmidlife risk factors tested were diabe-
tes mellitus, depressed mood, head trauma, central obesity,
lung function, and smoking. Although the original CAIDE
study used clinically established cut points, the current study
had ample power for more discrete categorization of some
continuous variables, and prior work in our population has
shown associations with even moderately elevated vascular
risk factors at midlife [18]. Thus, we also ran analyses
with recategorized cholesterol, SBP, and BMI values using
the following cut points: cholesterol, less than 200 mg/dL,
200 mg/dL to 239 mg/dL, and more than 239 mg/dL; SBP,
less than 120 mmHg, 120 mmHg to 129 mmHg, 130
mmHg to 139 mmHg, and more than 140 mmHg; and
BMI less than 18.5 kg/m2, 18.5 kg/m2 to 24.9 kg/m2, 25
kg/m2 to 29.9, and more than 30 kg/m2.
Improvements in performance of the CAIDE risk score
by adding a new risk factor were measured by the net
reclassification improvement (NRI) and the integrated
discrimination improvement (IDI) statistics [19,20]. The
NRI can be interpreted as a measure of correctness
of upward and downward movement of predicted
probabilities as a result of adding a new marker. The NRI
is calculated by first estimating the difference in
probability that the new model improves risk prediction
and the probability that the new model worsens risk
prediction, separately for both events and for nonevents at
40 years. Positive values indicate that prediction gains
exceed losses, using the new covariate. The overall NRI is
the sum of the NRIs for events and nonevents [20]. The
IDI assesses improvement in risk discrimination (i.e., how
well a model separates subjects with disease compared
with those without disease) by estimating the change in the
difference in the mean predicted probabilities of the
outcome between those with and without the outcome
(e.g., dementia), after introducing the new risk factor to
the model. Positive values indicate improved discrimination.
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proportion of variance explained by the model (an R2-like
statistic for survival distributions, similar to that for linear
regression), with and without the new predictor [20]. All
analyses were performed using SAS version 9.1 (SAS Insti-
tute, Cary, NC). The SAS macro published by Chambless
et al. [17] was used for calculating the NRI and IDI
statistics and associated bootstrap confidence intervals,
and the Hosmer-Lemeshow calibration test. The NRI
calculation is dependent on the choice of risk categories;
thus, different cut points to define low-, middle-, and high-
risk dementia groups (0%–15%, 15%–25%, more than
25% vs. 0%–10%, 10%–20%, and more than 20%) were
evaluated.3. Results
A total of 2767 patients (25%) received a diagnosis of any
type of dementia, on average, 36.96 4.1 years after theirmid-
life MHC examination. A total of 1011 patients (11%)
received a medical specialist-confirmed dementia diagnosis,Table 1
Sociodemographic and risk factor characteristics of the study population stratified
Characteristics
Dementia
Yes
(n 5 1011)
No
(n 5
Population information
Race, n (%)
Asian 39 (4) 43
Black 209 (21) 119
White 763 (75) 684
Dementia diagnosis, n (%)
Age at dementia diagnosis, years; mean
(SD)
81.8 (5.0)
The original variables
Age at baseline, years; mean (SD) 47.9 (4.3) 45.
Education, n (%)
.9 years 440 (44) 404
7–9 years 376 (37) 306
0–6 years 195 (19) 136
Men, n (%) 408 (40) 384
Cholesterol, .250.9 mg/dL; n (%) 298 (29) 210
BMI, .30 kg/m2; n (%) 97 (10) 75
SBP, .140 mm/Hg; n (%) 189 (19) 154
Time from MHC, years; mean (SD)y 33.9 (4.1) 36.
Other new variables, n (%)
Central obesityz 161 (16) 115
Depressed mood 190 (19) 162
Diabetes mellitus 152 (15) 118
Head trauma 68 (7) 51
Poor pulmonary functionx 262 (26) 178
Smoking{ 530 (52) 486
Abbreviations: SD, standard deviation; BMI, body mass index; SBP, systolic b
NOTE. P values were calculated using the c2 test.
*Significant P value less than .05.
yTime from MHC to end of follow-up (including censor).
zCentral obesity: sagittal abdominal diameter, more than 25 cm.
xPoor pulmonary function: forced expiratory volume, 0.2 to 1.8 liters (lowest q
{Smoking: current and former.of which 816 were AD and 265 were vascular dementia. For
the 12,247 individuals in the validation cohort, the mean age
at the midlife assessment was 46.46 4.4 years, the mean age
at the start of dementia ascertainment was 72.46 4.6 years,
and the mean age at end of follow-up was 83.1 6 4.9 years.
For the 9480 individuals also included in the refinement
cohort, the mean age at the midlife assessment was 46.1 6
4.3 years, the mean age at the start of dementia ascertainment
was 73.1 6 4.5 years, and the mean age at end of follow-up
was 82.26 5.2 years. All results concern the refinement co-
hort unless otherwise specified. The mean age at the midlife
assessment was 46.16 4.3 years, the mean age at the start of
dementia ascertainment was 73.16 4.5 years, and the mean
age at end of follow-up was 82.26 5.2 years. Compared with
subjectswhodid not develop dementia during follow-up, sub-
jects that became demented were older, less educated, more
likely to be female, and more likely to have central obesity,
poor pulmonary function, and to be currently smoking at
baseline (Table 1).
The C statistic associated with the CAIDE risk score
logistic regression model for specialist-confirmed dementiaby dementia diagnosis and by race
Race
8469)
Asian
(n 5 474)
Black
(n 5 1401)
White
(n 5 7605)
5 (5)*
2 (14)*
2 (81)*
39 (8) 209 (15) 763 (10)
82.33 (4.8)* 80.8 (4.7)* 82.0 (5.1)*
9 (4.3)* 44.8 (4)* 45.6 (4.1)* 46.2 (4.3)*
1 (48)* 246 (52)* 343 (24)* 3892 (51)*
7 (36)* 158 (33)* 655 (47)* 2630 (35)*
1 (16)* 70 (15)* 403 (29)* 1083 (14)*
6 (45)* 243 (51)* 567 (40)* 3444 (45)
1 (25)* 115 (24) 396 (28)* 1888 (25)*
1 (9) 9 (2)* 264 (19)* 575 (8)*
7 (18) 67 (14)* 413 (29)* 1256 (17)*
4 (4.3)* 37.1 (4)* 35.9 (4.4)* 36.1 (4.3)
5 (14)* 27 (6)* 343 (24)* 946 (12)*
1 (19) 55 (12)* 316 (23)* 1440 (19)
6 (14) 85 (18)* 201 (14) 1052 (14)
5 (6) 6 (1)* 52 (4)* 525 (7)*
1 (21)* 171 (36) 518 (37)* 1357 (18)*
5 (57)* 189 (40)* 776 (55) 4430 (58)*
lood pressure; MHC, multiphasic health checkup.
uintile).
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dementia diagnosis in our validation cohort was 0.688. The
CAIDE score also performed well by race subtypes. Race
stratification of the risk score model showed a C statistic of
0.812 for Asian, 0.750 for black, and 0.735 for white.
The odds ratio and the hazard ratio, and the size and
direction of the b coefficient of the risk score are shown
for the six CAIDE risk score variables in one model
(Table 2). The b coefficient of age is larger based on the
Cox proportional hazard model compared with the b coeffi-
cient of the logistic model (e.g., 0.90 vs. 0.15 for the age
category 47 years–53 years). The odds ratio and the hazard
ratio of the six additional new risk factors based on six dif-
ferent models with the CAIDE model plus one additional
new risk factor are shown in Table 2.
The added value of all the new variables was verymodest,
with the C statistic almost unaffected (Table 3). The CTable 2
Multivariate analysis of possible risk factors for dementia
Variables
Logistic Cox proportional hazard
Odds ratio
(95% CI) b
Hazard ratio
(95% CI) b
Original variables
Age, years
,47 1 0 (ref) 1 0 (ref)
47–53 1.58 (1.37–1.83) 0.15* 2.46 (2.15–2.81) 0.90*
.53 1.61 (1.27–2.06) 0.17* 4.44 (3.59–5.49) 1.49*
Education, years
0–6 1.14 (0.94–1.37) 0.07 1.20 (1.01–1.43) 0.18*
7–9 1.04 (0.90–1.22) 20.01 1.06 (0.93–1.22) 0.06
.9 1 0 (ref) 1 0 (ref)
Gender
Male 0.74 (0.64–0.85) 20.15* 0.96 (0.84–1.09) 20.04
Cholesterol,
mg/dL
.250.9 1.09 (0.94–1.27) 0.04 1.21 (1.06–1.39) 0.19*
BMI, kg/m2
.30 0.98 (0.77–1.23) 20.01 1.19 (0.96–1.48) 0.18
SBP, mm/Hg
.140 0.75 (0.63–0.89) 20.15* 1.02 (0.87–1.21) 0.02
New variables
Central obesityy
Yes 1.05 (0.84–1.31) 0.17 1.27 (1.04–1.56) 0.24*
Depressed mood
Yes 0.88 (0.74–1.05) 20.06 1.02 (0.87–1.20) 0.02
Diabetes mellitus
Yes 1.07 (0.89–1.30) 0.03 1.05 (0.88–1.24) 0.04
Head trauma
Yes 1.05 (0.80–1.39) 0.14 1.22 (0.95–1.57) 0.20
Poor lung functionz
Yes 0.96 (0.81–1.15) 20.02 0.85 (0.72–1.00) 20.16*
Smokingx
Yes 0.70 (0.61–0.81) 20.18 1.00 (0.89–1.14) 0.00
Abbreviations: CI, confidence interval; ref, reference; BMI, body mass
index; SBP, systolic blood pressure.
NOTE. Original variables are from all six CAIDE variables in one model.
The next section, New variables, presents six different models: the six
CAIDE variables plus one new variable.
*Significant at P less than .05.
yCentral obesity: sagittal abdominal diameter, more than 25 cm.
zPoor pulmonary function: forced expiratory volume, 0.2 to 1.8 liters
(lowest quintile).
xSmoking: current and former.statistic of the original CAIDE score generated from the
Cox proportional hazards model is less than the one from
the logistic model (0.665 vs. 0.747). This difference likely
represents a slight overfitting of the logistic model; Cox
models account more accurately for right censoring and
loss to follow-up. The lower C statistic in the validation co-
hort (0.688) compared with the refinement cohort (0.747)
can be explained by more false-positive dementia cases in
the “possible dementia” diagnosis in the validation cohort.
The C statistic of both the logistic and the Cox models did
not change with the addition of new risk factors. More dis-
crete categorization of BMI, SBP, and cholesterol also did
not improve prediction (data not shown here).
NRI and IDI statistics were also used to evaluate potential
predictive improvement. Table 3 shows that similar to the C
statistic, theNRI (cut points, 0%–15%, 15%–25%,more than
25%) and IDI calculations shownomodel improvements. For
example, the addition of central obesity causes a reclassifica-
tion toward incorrect assignment, shown by a decrease in the
net reclassification by 1.5%. The calibration decreased, as
shown by the increase in the Hosmer Lemeshow c2 value
from 17 to 28.5. Adding smoking improved the calibration
slightly; the Hosmer Lemeshow c2 value decreased from
17 to 7.2; however, there was no reclassification. The NRI
analysis with the cut points 0% to 10%, 10% to 20%, and
more than 20%, to define the low-, middle-, and high-risk
group generated similar results (not shown).
The riskof dementia is reportedper sumscore (Fig. 1). Sum
scores greater than 7 points (i.e., 8–14 points) were relatively
rare; thus, the risk estimates were less stable for the very high-
est scores. Therefore, scores greater than 7 pointsweremerged
into one category for the Kaplan-Meier estimated dementia
risk.Therewas a threefold difference indementia riskbetween
the lowest sum score of 1 point (associated Kaplan-Meier es-
timate, 9%) and the highest sum score of 8 points or more (as-
sociated Kaplan-Meier estimate, 29%). The summary of the
risk score for dementia is shown in Fig. 2.4. Discussion
The CAIDE midlife dementia risk score replicated well
in our large, diverse cohort. Indeed, it was possible to
stratify participants into those with 40-year low (9%)
and high (29%) dementia risk. The predictability of the
risk score in our cohort (C statistic, 0.75) was quite com-
parable with the original CAIDE cohort (0.78). The
CAIDE risk score also performed well within race sub-
types: Asian C statistic, 0.81; black C statistic, 0.75; and
white C statistic, 0.74.
Somewhat surprisingly, the addition of several “new” mid-
life risk factors, not available in CAIDE, did not enhance the
predictability of the risk score as tested by the C statistic.
The application of novel statisticalmethods to investigate clin-
ical meaningful improvement by NRI and IDI also did not
show an improvement. There are some potential reasons
why additional midlife risk factors did not improve the risk
Table 3
Added value of adding a variable to the original CAIDE model
No. Model name
Discrimination Calibration Reclassification improvement
C statistic HL NRI* IDI
Logisticy Coxz c2x P value Event Nonevent Estimate 95% CI Estimate 95% CI
1. CAIDE 0.747 0.665 17.0084 .0300
2. 1 1 central obesity 0.747 0.668 28.5453 .0004 2.0242 .0096 2.0145 2.0233 to .0257 .0014 .0000–.0050
3. 1 1 depressed mood 0.747 0.665 20.7744 .0078 2.0204 .0110 2.0093 2.0270 to .0344 .0000 2.0000 to .0015
4. 1 1 DM 0.747 0.665 22.1899 .0046 2.0353 .0199 2.0153 2.0234 to .0311 .0000 2.0001 to .0001
5. 1 1 head trauma 0.747 0.665 24.4681 .0019 2.0210 .0149 2.0060 2.0204 to .0253 .0005 2.0000 to .0026
6. 1 1 poor lung function{ 0.747 0.666 5.1746 .7388 2.0104 .0021 2.0082 2.0268 to .0355 .0006 2.0000 to .0030
7. 1 1 smoking# 0.749 0.665 7.1978 .5155 0** 0** 0** 0**
Abbreviations: HL, Hosmer Lemeshow goodness of fit test; NRI, net reclassification improvement; IDI, integrated discrimination improvement; CI, confi-
dence interval: CAIDE, cardiovascular risk factors, aging and dementia; DM, diabetes mellitus.
NOTE. Results of NRI and IDI analysis are expressed as differences in probabilities with 95% CI based on bootstrap procedure.
*NRI was used to compare model 1 (CAIDE) with models 2 through 7, with cut points 15% and 25%.
yC statistic based on logistic regression analyses.
zC statistic based on Cox proportional hazard regression analyses.
xHosmer Lemeshow test c2 is presented.
{Poor pulmonary function with a forced expiratory volume of 0.2 to 1.8 liters (lowest quintile).
#Smoking: current and former.
**Not onemember of the cohort had a change in risk prediction category with the addition of smoking to themodel—thus, zero for NRI and IDI, and bootstrap
CIs were incalculable.
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with the original predictors, such as central obesity with BMI.
The combination of high BMI, high SBP, and high cholesterol
in the original CAIDE risk score likely represents a metaboli-
cally risky phenotype. Further addition ofmidlife vascular risk
factors to this metabolic risk phenotype may not amplify pre-
dictability. Second, some additional risk factors are known to
be risk factors both inmidlife and later in life, but have a higher
prevalence later in life, such as type 2 diabetes mellitus and
head trauma. The population-attributable risk of type 2 diabe-
tes mellitus and head trauma at midlife might be too low. A
possible etiological role of any of the midlife risk factors can-
not be deduced from the current prediction study.
Our study has several strengths. Awide breadth of detailed
midlife information was available for our cohort. ParticipantsFig. 1. Plot of probability of dementia in late life according to the risk score catego
40-year dementia risk per sum score with a 95% confidence interval.could be monitored for up to an average age of 82.2 6 5.2
years, compared with 71.3 6 4.0 years in CAIDE. Another
benefit of the study design is that the current cohort had
more than a 12-year period to ascertain a dementia diagnosis,
in contrast to the CAIDE cohort, in which the participants
were evaluated for dementia at one time point in late life.
The model was tested in different race groups, a significant
contribution given the rapidly increasing ethnic diversifica-
tion in the elderly population in the United States. Last, we
used survival analysis techniques (Cox regression and
Kaplan-Meier estimates) in a longitudinal follow-up and ap-
plied novel risk score testing, including IDI and NRI, not
used previously in dementia prediction.
Limitations of the study include the use of diagnostic codes
for dementia rather than a standardized assessment given to allries in midlife. Kaplan-Meier estimates were used to calculate the observed
Fig. 2. Risk score to predict 40-year risk of dementia. Steps 1 through 6 are based on the original cardiovascular risk factors, aging and dementia (CAIDE) score;
the predicted 40-year risk of dementia is based on the current study.
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tion of dementia (i.e., not all cases of dementia will be diag-
nosed and recorded) and overdetection (i.e. not all
participants with a physician-recorded diagnosis of dementia
will have dementia). Nevertheless, based on a recent study,
the use of the same ICD-9 codes for dementia was found to
have a sensitivity of 77% and a specificity of 95% compared
with a consensus diagnosis of dementia based on a neuropsy-
chiatric battery, physical examination, structured interview
with informants, and review of medical records in a clinic-
based setting [21]. Moreover, an advantage of this passive
case identification is the absence of refusal bias. The exclusion
of those with a diagnosis of general dementia from a primary
care physician who did not, subsequently, get diagnosed by
amedical specialist for the second aimof our study (the refine-
ment of the risk score) likely resulted in underrecognition of
some dementia cases. However, this approach increases the
specificity for the outcome, which we considered particularly
important for this second aim. Another limitation of the study
is that dementia ascertainment was initiated, on average,
26 years after the baseline assessment, at an average age of
73.1 years. Subjects that participated in the midlife examina-
tion (n 5 18,231) had to survive and remain a member of
KP to be able to be included in the 12-year follow-up starting
in 1994 (n5 14,282). This study design is subject to attrition
and possible immortal person-year time bias of the interval
between midlife (1964–1973) and 1994. Use of the Cox pro-
portional hazards model with censoring for death and gaps
in health planmembership during the 12-year dementia ascer-
tainment periodminimizes confounding by survival bias from
1994 to2006, but not before 1994.Another potentialweakness
is the absence of a physical activity variable similar to the oneused in the original CAIDE study [10]. However, in the
CAIDE study, midlife physical activity was not associated
significantly with dementia risk, but was kept in their final
model to highlight its importance as a healthy lifestyle factor.
Other than the CAIDE dementia risk score, three late-life
dementia risk scores focusing on short-term prediction in the
elderly have been published [22–24]. All risk scores
identified older age as an important predictor; however,
other findings differed. Predictors in CAIDE (midlife) are
primarily cardiovascular risk factors, whereas late-life mea-
sures reflect the cumulative long-term impact of vascular
risk factors on the brain. A dementia midlife risk score is
a screening tool to be used in the general population; there-
fore, predictors need to be noninvasive, cheap, and easily at-
tainable. Early markers of disease such as magnetic
resonance imaging abnormalities can be used for dementia
prediction in an elderly population with subjects who al-
ready have preclinical stages of dementia, but may be inap-
propriate for use in a midlife population.
The main use of a risk score is to target preventive mea-
sures to those most at risk. A recently published review [25]
regarding potentially modifiable risk factors showed that
a 10% reduction in midlife obesity prevalence could poten-
tially prevent about 67,000 AD cases worldwide and 36,000
cases in the United States. Unfortunately, most prevention
studies have been conducted in the elderly. The few studies
in midlife suggest that lipid-lowering drugs [26] and
a healthy diet [27] in midlife may have a beneficial effect
in dementia prevention. A multicenter, randomized, con-
trolled clinical trial showed there was no difference in de-
cline between elderly patients with mild dementia that
received strict cardiovascular treatment vs. patients that
L.G. Exalto et al. / Alzheimer’s & Dementia 10 (2014) 562–570 569received standard care [28]. This highlights the importance
of the timing of prevention trials and suggests a promising
role for a midlife dementia risk score.
Even though dementia becomes apparent in older age,
recent evidence has illustrated that it is a disease of a life-
time. Early detection of those at increased risk of dementia
may help to develop and target preventive treatment strat-
egies. Implications of the CAIDE score suggest that
long-term maintenance of vascular health may delay or
prevent dementia [25]. It is projected that even a modest
1-year delay in the onset of AD would result in 11.8 mil-
lion fewer cases after 50 years [1]. The current findings
demonstrate that a combination of mostly modifiable vas-
cular risk factors in midlife is highly predictive of the like-
lihood of dementia four decades later in a large
representative population. Application of the current risk
score would allow subjects at high risk for dementia to
be selected for clinical trials and early intervention or
prevention studies as early as midlife.Acknowledgments
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1. Systematic review: Dementia prevention trials have
not yet shown the desired effect. To increase
chances of successful future trials, enrichment of
study cohorts through risk stratification is needed.
We searched PubMed for dementia risk scores.
2. Interpretation: As a result of the long prodromal
stage of dementia, and the potential for risk factor
modification, valid dementia risk stratification in
midlife is imperative. Although several dementia
risk scores using predictors in late life to predict
short-term risk of dementia have been published,
only the CAIDE score used predictors in midlife to
predict dementia in the elderly 20 years later.
However, the cardiovascular risk factors, aging and
dementia (CAIDE) score has not been validated ex-
ternally. It is unknown how it performs in larger,
diverse populations and whether it can be improved
through testing of other midlife risk factors.
3. Future directions: The CAIDE risk score predicted
well in our population. Application of the risk score
to select subjects in midlife at high risk for dementia
is useful for future clinical trials andprevention studies.References
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